Value Proposition

  • Combining one of the world's most innovative drug discovery platforms with development of novel, best-in-class therapies.


Broadly Experienced Management Team

  • Extensive expertise in drug discovery and development in large opportunity markets in oncology and CNS.

  • Deep understanding of ion channel physiology and CNS drug design.


Robust Clinical Development Programs

  • Lead development program BNC210 is a negative allosteric modulator alpha 7 nicotinic acetylcholine receptor.

  • BNC210 made strong progress in the clinic reporting positive Phase 2 clinical trial results in a Generalised Anxiety Disorder (GAD) patient population.

  • The treatment phase of a large multinational Phase 2 clinical trial evaluating BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) is complete, and results are anticipated in later Quarter 3, 2018.

  • A Phase 2 clinical trial is currently recruiting elderly patients with agitation in specialist geriatric hospital wards across Australia to evaluate the effect of BNC210 on the resolution of agitation in this population. Results are anticipated in Quarter 1, 2019.

Three Proprietary Technology Platforms 

  • Multicore®: suite of integrated pharmacophore modelling and synthetic methods for generating chemical diversity enabling rapid drug candidate identification.
  • ionX®:  integrated platform technologies that serve as the foundation of Bionomics' CNS drug discovery and development activities.

Strong Cash Position

  • Solid balance sheet.

  • Cash balance of AU$32.25M (as of 31 Dec 2017) to support robust clinical development programs.

  • Cash receipts for the period included receipts from customers totalling $0.900M for the quarter ending 31 March 2018.  Bionomics recieved an R&D Tax Incentive refund of $6.788M in January 2018.

  • Market Cap: AU$206M (as at 21 May 2018).